Status:
COMPLETED
Alternate Day Buprenorphine Administration, Phase XI - 16
Lead Sponsor:
University of Vermont
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Opioid-Related Disorders
Eligibility:
All Genders
25-51 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate open buprenorphine dosing with dose choice after open exposure.
Eligibility Criteria
Please contact site for information.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000234
Last Update
May 6 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Treatment Research Center
Burlington, Vermont, United States, 05401